Dementia Associated with Alzimer’s Disease Market [Drug Class: Cholinergic/ Cholinesterase Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Report Highlights
Dementia Treatment Market - Overview
This report analyzes the current and future scenario of the global dementia associated with Alzheimer’s disease market for the period 2018 to 2026. Rise in geriatric population, increased prevalence of Alzheimer’s, high unmet medical needs, and rich pipeline are likely to be major drivers of the global dementia associated with Alzheimer’s disease market during the forecast period.
The dementia associated with Alzheimer’s disease market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the dementia associated with Alzheimer’s disease market.
Dementia Associated with Alzheimer’s Disease Market: Key Segments
Based on drug class, the global dementia associated with Alzheimer’s disease market has been segmented into cholinergic/ cholinesterase (ChE) inhibitors, memantine, and combined drug (memantine & donepezil) and others. The segments have been analyzed based on available drugs used during the treatment of AD and cost-effectiveness. In terms of distribution channel, the global dementia associated with Alzheimer’s disease market has been divided into hospital pharmacies, retail, and online sales. Based on market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.
Dementia Associated with Alzheimer’s Disease Market: Regional Outlook
In terms of region, the global dementia associated with Alzheimer’s disease market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in the Report
The report also profiles major players operating in the global dementia associated with Alzheimer’s disease market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd.
The global dementia associated with Alzheimer’s disease market has been segmented as below:
Dementia Associated with Alzheimer’s Disease Market, by Drug Class
Cholinergic/ Cholinesterase (ChE) Inhibitors
Memantine
Combined Drug (Memantine & Donepezil) and Others
Dementia Associated with Alzheimer’s Disease Market, by Distribution Channel
Hospital Pharmacies
Retail
Online Sales
Dementia Associated with Alzheimer’s Disease Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
GCC Countries
Rest of Middle East & Africa
- Table 1 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 2 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Cholinergic/ Cholinesterase (ChE) Inhibitors, 2016–2026
- Table 3 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 4 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Region, 2016–2026
- Table 5 : North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country, 2016–2026
- Table 6 : North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 7 : North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
- Table 8 : North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 9 : Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
- Table 10 : Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 11 : Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
- Table 12 : Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 13 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
- Table 14 : Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 15 : Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
- Table 16 : Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 17 : Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
- Table 18 : Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 19 : Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
- Table 20 : Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 21 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
- Table 22 : Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
- Table 23 : Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
- Table 24 : Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–202
- Figure 1 : Dementia Associated with Alzheimer's Disease Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
- Figure 2 : Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018(E)
- Figure 3 : Dementia Associated with Alzheimer's Disease Market Snapshot
- Figure 4 : Dementia Associated with Alzheimer's Disease Market Value Share
- Figure 5 : Dementia Associated with Alzheimer's Disease Market Value Share
- Figure 6 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, 2016–2026
- Figure 7 : Global Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017
- Figure 8 : Global Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017
- Figure 9 : Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2017
- Figure 10 : Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Drug Class, 2018 and 2026
- Figure 11 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholinergic/ Cholinesterase (ChE)Inhibitor
- Figure 12 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Memantine
- Figure 13 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combined Drug (Memantine & Donepezil) and Others
- Figure 14 : Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Drug Class, 2018–2026
- Figure 15 : Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 16 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies
- Figure 17 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail
- Figure 18 : Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Sales
- Figure 19 : Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Distribution Channel
- Figure 20 : Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2018 and 2026
- Figure 21 : Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Region, 2018–2026
- Figure 22 : North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
- Figure 23 : North America Dementia Associated with Alzheimer's Disease Market Value Share, by Country, 2017 and 2026
- Figure 24 : North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country, 2018–2026
- Figure 25 : North America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
- Figure 26 : North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
- Figure 27 : North America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
- Figure 28 : North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
- Figure 29 : Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
- Figure 30 : Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
- Figure 31 : Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
- Figure 32 : Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
- Figure 33 : Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
- Figure 34 : Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
- Figure 35 : Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
- Figure 36 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
- Figure 37 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
- Figure 38 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
- Figure 39 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
- Figure 40 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
- Figure 41 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
- Figure 42 : Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
- Figure 43 : Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
- Figure 44 : Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
- Figure 45 : Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
- Figure 46 : Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
- Figure 47 : Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
- Figure 48 : Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
- Figure 49 : Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
- Figure 50 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
- Figure 51 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
- Figure 52 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
- Figure 53 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
- Figure 54 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
- Figure 55 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
- Figure 56 : Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
- Figure 57 : Merz Pharma GmbH & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
- Figure 58 : Merz Pharma GmbH & Co. KGaA R&D Expenses, 2016–2017
- Figure 59 : Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Region, 2017
- Figure 60 : Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Business Segment, 2017
- Figure 61 : Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
- Figure 62 : Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
- Figure 63 : Novartis AG Breakdown of Net Sales, by Region, 2017
- Figure 64 : Novartis AG Breakdown of Net Sales, by Business Segment, 2017
- Figure 65 : Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
- Figure 66 : Allergen plc. R&D Expenses, 2016–2017
- Figure 67 : Allergan plc. Sales and Marketing Expenses, 2017
- Figure 68 : Allergan plc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 69 : Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
- Figure 70 : Pfizer, Inc. R&D Expenses and SI&A Expenses (%) 2015–2017
- Figure 71 : Pfizer, Inc. Breakdown of Net Sales, by Geography (Essential Health Segment), 2017
- Figure 72 : Pfizer, Inc. Breakdown of Net Sales, by Product (%), 2017
- Figure 73 : Daiichi Sankyo Company, Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
- Figure 74 : Daiichi Sankyo Company, Limited R&D Expenses (US$ Bn), 2016–2017
- Figure 75 : Daiichi Sankyo Company, Limited Breakdown of Net Sales, by Region, 2017
- Figure 76 : Ono Pharmaceutical Co., Ltd. Research & Development Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
- Figure 77 : Ono Pharmaceutical Co., Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
- Figure 78 : Ono Pharmaceutical Co., Ltd. Breakdown of Net Sales, by Geography, 2017
- Figure 79 : Johnson & Johnson Services, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
- Figure 80 : Johnson & Johnson Services, Inc. Pharmaceutical Products Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
- Figure 81 : Johnson & Johnson Services, Inc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 82 : Johnson & Johnson Services, Inc. Research & Development Cost, 2015 – 2017 (US$ Bn)
- Figure 83 : Eisai Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 84 : Eisai Co., Ltd. Breakdown of Net Sales, by Business
- Figure 85 : H. Lundbeck A/S Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
- Figure 86 : H. Lundbeck A/S Breakdown of Net Sales, by Region, 2017
- Figure 87 : H. Lundbeck A/S Research & Development Cost, 2015 – 2017 (US$ Mn)
- Figure 88 : F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2017
- Figure 89 : F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
- Figure 90 : F. Hoffmann-La Roche Ltd. Research & Development Cost, 2015 – 2017 (US$ Bn
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.